All News

Before jumping on the gold bandwagon, it is important to understand the market factors that impact gold pricing, and how this unique commodity may or may not fit into your overall investment portfolio.

Laparoendoscopic single-site surgery (LESS) has evolved to the point that a broad range of urologic procedures can be performed effectively and safely by applying different techniques.

Physician organizations nationwide, including the AUA, have united in opposition to many provisions of a plan by the Centers for Medicare & Medicaid Services to sell Medicare claims data to qualified businesses that would generate public reports rating physician performance in each episode of care.

Analyses of data from a large series of men undergoing microdissection testicular sperm extraction (mTESE) showed that among patients who had no sperm found in the OR, 7% had sperm identified following tissue digestion and extensive searching in the laboratory.

Utilization trends for minimally invasive treatment of prostate cancer appear to be similar across sites of service, a recent study indicates.

Seasonal variations in kidney stone incidence appear to be reflected in Google search engine queries, according to researchers at the University of California, San Francisco.

Long-term use of degarelix (Firmagon), a gonadotropin-releasing hormone therapy approved for the treatment of advanced prostate cancer in both Europe and the United States, continues to be effective and well tolerated beyond 3 years, according a recent study.

New guidelines from the American Academy of Pediatrics do not recommend routine use of voiding cystourethrography (VCUG) after the first urinary tract infection in febrile infants and children aged 2 to 24 months.

In men with erectile dysfunction, 65% are unable to have an orgasm and 58% have problems with ejaculation, say researchers from New York-Presbyterian Hospital/Weill Cornell Medical Center.

The FDA recently approved onabotulinumtoxinA (Botox) injection for the treatment of urinary incontinence due to detrusor overactivity associated with a neurologic condition (eg, spinal cord injury, multiple sclerosis) in adults who have an inadequate response to or are intolerant of an anticholinergic medication.

Passive management is an investment strategy that attempts to replicate the returns of an index or benchmark by owning the same assets, in the same proportions, as the underlying index. Active managers attempt to outperform the market through the art of stock picking and market timing.

Physical therapists have responded to the high costs of physical therapy for CP/CPPS (often not covered by insurance) by helping patients learn to massage their own pelvic floor muscle trigger points with internal massage tools. Now, there's evidence that this at-home, self-treatment approach works.

New analyses of data from the phase III study establishing the superiority of denosumab (XGEVA) to zoledronic acid (Zometa) for preventing skeletal-related events in men with bone metastases from castrate-resistant prostate cancer provide further evidence of the therapeutic value of the novel bone-targeted agent.

An embolization technique employing 100-?m or 200-?m polyvinyl beads delivered through the femoral artery and into prostatic arteries to block the latter and shrink prostate volume in men with BPH produces short- and mid-term results equivalent to transurethral resection of the prostate.

The high selectivity of the alpha-blocker silodosin (Rapaflo) may be the reason for its success in treating CP/CPPS in a recent trial.

The proximity of the gracilis and sartorius muscles to the perineal and inguinal regions, respectively, makes them ideal muscle flaps to reconstruct some urologic defects.

According to one well-refined simulation model, the cost in current dollars of treating 100 prostate cancer patients initially enlisted in an active surveillance program is $2,702,191 over 5 years. This is $1,013,422 less expensive per 100 men than any of the available immediate interventional therapies over the same span and could translate to substantial national savings.

During the debate about increasing the debt ceiling, the targeting of entitlements in cuts came as little surprise to urologists.

AUA Health Policy Chair Steven M. Schlossberg, MD, MBA, discusses important health policy issues in urology and how the AUA is addressing them.

Urologists are acutely aware of the cost of prostate cancer treatments and how they may impact patients' lives.

A high-volume surgeon will have good results regardless of approach, but that the surgeon with less experience might do a better job with the robotic approach.

Despite defeats of bills in several states, some urologists believe that threats to urologists' ability to provide ancillary services-essentially, their ability to furnish integrated health care-are not going away.

The national budget crisis that has consumed Washington threatens to worsen the outlook for physicians, urologists included, who hope to avoid a 29.5% Medicare payment reduction scheduled for Jan. 1, 2012 unless Congress acts once again to avert it.

Here are billing specifics for sipuleucel-T (Provenge) that you need to know.

After a median follow-up of 10 years, the intent-to-treat with radical prostatectomy did not significantly reduce all-cause or prostate cancer-specific mortality compared with active surveillance.

Men with chronic prostatitis/chronic pelvic pain syndrome appear to have a higher incidence of endothelial dysfunction and arterial stiffness, providing a possible link to cardiovascular disease in these patients.

Setting boundaries and appropriate processes for handling e-mail correspondence with patients can address many of the concerns urologists have about e-mailing patients.